Lipoteichoic Acid antibody

Catalog No. ABIN7232846

The Mouse Monoclonal anti-Lipoteichoic Acid antibody has been validated for ELISA. It is suitable to detect Lipoteichoic Acid in samples from Gram Positive Bacteria.

Quick Overview for Lipoteichoic Acid antibody (ABIN7232846)

Target: Lipoteichoic Acid (LTA)

Reactivity: Gram Positive Bacteria

Host: Mouse

Clonality: Monoclonal

Conjugate: This Lipoteichoic Acid antibody is un-conjugated

Application: ELISA

Clone: 15711

Product Details anti-Lipoteichoic Acid Antibody

Purpose: Anti-Lipoteichoic Acid Mouse Monoclonal Antibody

Specificity: This antibody reacts with lipoteichoic acid of Staph epidermidis, Hay strain, as well as clinical strains of Staph. epidermidis (types I, II, and III), Staph. aureus strains 5 and 8, Strep. pyogenes, Strep. fecaelis, and Strep. mutans. It does not react with peptido- glycan of Staph. aureus or peptidoglycan- rhamnose, nor does it react with pneumococcal polysaccharides. This antibody does not cross-react with E. coli or H. influenzae type B.

Cross-Reactivity: Gram Positive Bacteria

Immunogen: Staphylococcus epidermidis, Hay strain (ATCC #55133).

Isotype: IgG1

Application Details

Application Notes: ELISA: use at 0.1-1.0 μg/mL (optimized for LTA on solid phase).
Opsonization assay: use at 80-160 μg/mL (optimized for Staph. epidermidis, Hay strain).

Restrictions: For Research Use only

Handling

Format: Liquid

Reconstitution: Dilute in PBS or medium that is identical to that used in the assay system.

Concentration: Lot specific

Buffer: PBS, pH 7.4

Storage: -20 °C

Storage Comment: This antibody is stable for at least one (1) year at -20°C. Avoid multiple freeze-thaw cycles.

Target Details for Lipoteichoic Acid

Target: Lipoteichoic Acid (LTA)

Alternative Name: Lipoteichoic acid

Target Type: Chemical

Background: Lipoteichoic acid (LTA) is the major proinflammatory structure present within the cell wall layer of most gram-positive bacteria. It plays an important role in the initiation and progression of bacterial infection, inflammation, and septic shock. LTA induces several cytokines in vivo, and LTA and peptidoglycan (PepG) synergize to cause the induction of nitric oxide formation which can lead to multiple organ failure. Since LTA is also found in the cell walls of non-pathogenic gram-positive bacteria, it has been suggested that the structure of LTA , and its ability to synergize with PepG, determines the ability of a particular bacterium to cause septic shock.